1-3 of 3
Jacob J Riehm
Close
Sort by
Journal Articles

Abbv-101, a Highly Potent and Selective Clinical Stage Bruton Tyrosine Kinase Degrader for the Treatment of B-Cell Malignancies

Chin Pan, Tarikere L Gururaja, Haiyan Li, Henry Nguyen, Yongjiao Zhai, Xiaoping Xie, Rong-Xian Ding, Rebecca Mathew, Hana Y Hoh, Zhaozhong J Jia, Bo Liu, Cassandra Shu, Wissam Assaily, Lloyd T Lam, Jacob J Riehm, Claudina Stevenson, Christine Will, Federico Innocenti, Alexey Rivkin
Journal: Blood
Blood (2023) 142 (Supplement 1): 1887.
https://doi.org/10.1182/blood-2023-184835
Published: 2023
Journal Articles

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Brenda J Chyla, PhD, Jason Harb, PhD, Christine Mantis, PhD, Jacob J Riehm, PhD, Jeremy A. Ross, PhD, Yan Sun, PhD, Xin Huang, PhD MD, Qi Jiang, PhD, Monique Dail, PhD, Franklin V. Peale, Jr., MD PhD, Jalaja Potluri, MD, John Hayslip
Journal: Blood
Blood (2019) 134 (Supplement_1): 546.
https://doi.org/10.1182/blood-2019-128373
Published: 2019
Journal Articles

The BCL-2-Selective Inhibitor Venetoclax Spares Activated T-Cells during Anti-Tumor Immunity

Rebecca Mathew, PhD, Dipica Haribhai, PhD, Fred Kohlhapp, PhD, Ryan Duggan, Paul Ellis, Jacob J Riehm, Valerie A Robinson, Yan Y Shi, Anahita Bhathena, PhD, Joel D. Leverson, PhD, William N Pappano, Cherrie K Donawho, PhD, Tamar Uziel, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3704.
https://doi.org/10.1182/blood-2018-99-113134
Published: 2018